Company Overview of Breckenridge Pharmaceutical, Inc.
Breckenridge Pharmaceutical, Inc. researches, develops, and markets generic prescription products in various therapeutic categories. The company markets its products in various dosage forms, including tablets, capsules, soft gel capsules, liquids, suspensions, and powders. It also provides various medical foods for the dietary management of patients with therapeutic or chronic medical needs; and prenatal and dietary supplements. In addition, the company handles various aspects of business operations, including procurement, purchasing, inventory management, warehousing, distribution, transportation, and customer service support. It serves chains, managed care customers, wholesalers, and distr...
6111 Broken Sound Parkway NW
Boca Raton, FL 33487
Founded in 1983
Key Executives for Breckenridge Pharmaceutical, Inc.
Senior Vice President of Sales for New Jersey Office
Executive Vice President of CT Office
Vice President of Finance for Ct Office
Compensation as of Fiscal Year 2014.
Breckenridge Pharmaceutical, Inc. Key Developments
Breckenridge Pharmaceutical Signs Multi-Product Generic Agreement with Pharmaceutics International, Inc
Nov 25 14
Breckenridge Pharmaceutical, Inc. announced that it has entered into a multi-product ANDA agreement with Pii (Pharmaceutics International, Inc.) under which Breckenridge and Pii expect to develop and commercialize several new ANDA's. Under the terms of the agreement, Pii will develop, manufacture and supply the products, and Breckenridge will market and distribute the products under its own label. The drugs, comprised of four unique dosage forms, and have combined U.S. market sales in excess of $1.6 billion, in the 12-month period ending September 30, 2014. The multi-product agreement contemplates the submission of multiple ANDA's with Paragraph IV certifications.
Breckenridge Announces Approval of Quetiapine Fumarate Tablets
Nov 3 14
Breckenridge Pharmaceutical, Inc. announced the approval of Quetiapine Fumarate Tablets. Quetiapine Fumarate Tablets are AB rated to Seroquel a $395 million generic drug marketed by the AstraZeneca group of companies. Seroquel(R) is an atypical antipsychotic indicated for the treatment of Schizophrenia and Bipolar disorders. The product launch plans are still being finalized. Breckenridge's Quetiapine Fumarate Tablets are supplied under a deal with Medikl Ltd. Cyprus and are manufactured and supplied by Alembic Pharmaceutical's, the ANDA holder. The product will be supplied in 25, 50, 100, 200, 300 AND 400mg strengths.
Breckenridge Pharmaceutical, Inc. Announces Approval of Mefenamic Acid Capsules, USP 250mg
Oct 14 14
Breckenridge Pharmaceutical, Inc. announced the immediate launch of Mefenamic Acid 250mg Capsules. The U.S. Food and Drug Administration previously granted final approval for the Abbreviated New Drug Application (ANDA) for this product. This product is one of five approved Breckenridge ANDA products secured from the September 2013 acquisition of certain Cypress Pharmaceutical, Inc. product assets. Breckenridge's Mefenamic Acid Capsules are AB rated to Ponstel(R) a generic drug marketed by Shionogi Pharma, Inc., a $10.3 million generic based on August 2014 IMS Health sales data. Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the relief of mild to moderate pain in patients greater than or equal to 14 years of age, when therapy will not exceed one week (7 days). It is also indicated for the treatment of primary dysmenorrhea.
Similar Private Companies By Industry
Recent Private Companies Transactions